Cargando…

Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period

BACKGROUND/PURPOSE OF THE STUDY: Tumor heterogeneity based on copy number variations is associated with the evolution of cancer and its clinical grade. Clonal composition (CC) represents the number of clones based on the distribution of B-allele frequency (BAF) obtained from a genome-wide single nuc...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaibori, Masaki, Sakai, Kazuko, Matsushima, Hideyuki, Kosaka, Hisashi, Matsui, Kosuke, De Velasco, Marco A., Sekimoto, Mitsugu, Nishio, Kazuto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843910/
https://www.ncbi.nlm.nih.gov/pubmed/34973129
http://dx.doi.org/10.1007/s12072-021-10278-4
_version_ 1784651367628931072
author Kaibori, Masaki
Sakai, Kazuko
Matsushima, Hideyuki
Kosaka, Hisashi
Matsui, Kosuke
De Velasco, Marco A.
Sekimoto, Mitsugu
Nishio, Kazuto
author_facet Kaibori, Masaki
Sakai, Kazuko
Matsushima, Hideyuki
Kosaka, Hisashi
Matsui, Kosuke
De Velasco, Marco A.
Sekimoto, Mitsugu
Nishio, Kazuto
author_sort Kaibori, Masaki
collection PubMed
description BACKGROUND/PURPOSE OF THE STUDY: Tumor heterogeneity based on copy number variations is associated with the evolution of cancer and its clinical grade. Clonal composition (CC) represents the number of clones based on the distribution of B-allele frequency (BAF) obtained from a genome-wide single nucleotide polymorphism (SNP) array. A higher CC number represents a high degree of heterogeneity. We hypothesized and evaluated that the CC number in hepatocellular carcinoma (HCC) tissues might be associated with the clinical outcomes of patients. METHODS: Somatic mutation, whole transcriptome, and CC number based on copy number variations of 36 frozen tissue samples of operably resected HCC tissues were analyzed by targeted deep sequencing, transcriptome analysis, and SNP array. RESULTS: The samples were classified into the heterogeneous tumors as poly-CC (n = 26) and the homogeneous tumors as mono-CC (n = 8). The patients with poly-CC had a higher rate of early recurrence and a significantly shorter recurrence-free survival period than the mono-CC patients (7.0 months vs. not reached, p = 0.0084). No differences in pathogenic non-synonymous mutations, such as TP53, were observed between the two groups when targeted deep sequencing was applied. A transcriptome analysis showed that cell cycle-related pathways were enriched in the poly-CC tumors, compared to the mono-CC tumors. Poly-CC HCC is highly proliferative and has a high risk of early recurrence. CONCLUSION: CC is a possible candidate biomarker for predicting the risk of early postoperative recurrence and warrants further investigation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12072-021-10278-4.
format Online
Article
Text
id pubmed-8843910
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer India
record_format MEDLINE/PubMed
spelling pubmed-88439102022-02-23 Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period Kaibori, Masaki Sakai, Kazuko Matsushima, Hideyuki Kosaka, Hisashi Matsui, Kosuke De Velasco, Marco A. Sekimoto, Mitsugu Nishio, Kazuto Hepatol Int Original Article BACKGROUND/PURPOSE OF THE STUDY: Tumor heterogeneity based on copy number variations is associated with the evolution of cancer and its clinical grade. Clonal composition (CC) represents the number of clones based on the distribution of B-allele frequency (BAF) obtained from a genome-wide single nucleotide polymorphism (SNP) array. A higher CC number represents a high degree of heterogeneity. We hypothesized and evaluated that the CC number in hepatocellular carcinoma (HCC) tissues might be associated with the clinical outcomes of patients. METHODS: Somatic mutation, whole transcriptome, and CC number based on copy number variations of 36 frozen tissue samples of operably resected HCC tissues were analyzed by targeted deep sequencing, transcriptome analysis, and SNP array. RESULTS: The samples were classified into the heterogeneous tumors as poly-CC (n = 26) and the homogeneous tumors as mono-CC (n = 8). The patients with poly-CC had a higher rate of early recurrence and a significantly shorter recurrence-free survival period than the mono-CC patients (7.0 months vs. not reached, p = 0.0084). No differences in pathogenic non-synonymous mutations, such as TP53, were observed between the two groups when targeted deep sequencing was applied. A transcriptome analysis showed that cell cycle-related pathways were enriched in the poly-CC tumors, compared to the mono-CC tumors. Poly-CC HCC is highly proliferative and has a high risk of early recurrence. CONCLUSION: CC is a possible candidate biomarker for predicting the risk of early postoperative recurrence and warrants further investigation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12072-021-10278-4. Springer India 2022-01-01 /pmc/articles/PMC8843910/ /pubmed/34973129 http://dx.doi.org/10.1007/s12072-021-10278-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Kaibori, Masaki
Sakai, Kazuko
Matsushima, Hideyuki
Kosaka, Hisashi
Matsui, Kosuke
De Velasco, Marco A.
Sekimoto, Mitsugu
Nishio, Kazuto
Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period
title Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period
title_full Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period
title_fullStr Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period
title_full_unstemmed Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period
title_short Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period
title_sort patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843910/
https://www.ncbi.nlm.nih.gov/pubmed/34973129
http://dx.doi.org/10.1007/s12072-021-10278-4
work_keys_str_mv AT kaiborimasaki patientswithpolyclonalhepatocellularcarcinomaareatahighriskofearlyrecurrenceandhaveapoorrecurrencefreesurvivalperiod
AT sakaikazuko patientswithpolyclonalhepatocellularcarcinomaareatahighriskofearlyrecurrenceandhaveapoorrecurrencefreesurvivalperiod
AT matsushimahideyuki patientswithpolyclonalhepatocellularcarcinomaareatahighriskofearlyrecurrenceandhaveapoorrecurrencefreesurvivalperiod
AT kosakahisashi patientswithpolyclonalhepatocellularcarcinomaareatahighriskofearlyrecurrenceandhaveapoorrecurrencefreesurvivalperiod
AT matsuikosuke patientswithpolyclonalhepatocellularcarcinomaareatahighriskofearlyrecurrenceandhaveapoorrecurrencefreesurvivalperiod
AT develascomarcoa patientswithpolyclonalhepatocellularcarcinomaareatahighriskofearlyrecurrenceandhaveapoorrecurrencefreesurvivalperiod
AT sekimotomitsugu patientswithpolyclonalhepatocellularcarcinomaareatahighriskofearlyrecurrenceandhaveapoorrecurrencefreesurvivalperiod
AT nishiokazuto patientswithpolyclonalhepatocellularcarcinomaareatahighriskofearlyrecurrenceandhaveapoorrecurrencefreesurvivalperiod